Optiray 160 (Injection)
Generic name:ioversol (injection route) [ eye-oh-VER-sol ]
Drug class:Non-ionic iodinated contrast media
Medically reviewed by Drugs.com. Last updated on May 23, 2022.
Risks with Inadvertent Intrathecal AdministrationFor Intra-arterial and Intravenous Use OnlyInadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema .
The Optiray 160 brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
Commonly used brand name(s)
In the U.S.
- Optiray 160
- Optiray 240
- Optiray 300
- Optiray 320
- Optiray 350
Available Dosage Forms:
- Solution
Therapeutic Class: Radiological Non-Ionic Contrast Media
Uses for Optiray 160
Ioversol injection is used to help diagnose or find problems in the brain, heart, head, blood vessels, and other parts of the body. It is an iodinated contrast agent. Contrast agents are used to create a clear picture of the different parts of the body during certain medical procedures such as CT scans and angiography.
This medicine is to be given only by or under the supervision of a doctor.
Before using Optiray 160
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Optiray® 350 and Optiray® 320 for angiocardiography, and Optiray® 320 for CT scan of the head and body in children. However, safety and efficacy have not been established in children for Optiray® 300 and in children younger than 1 month of age for Optiray® 350 and Optiray® 320.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of ioversol injection in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require caution and an adjustment in the dose for patients receiving ioversol injection.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although..
